



Article

Toxicity of Jegosaponins A and B from *Styrax japonica* Siebold et al. Zuccarini in Prostate Cancer Cells and Zebrafish Embryos Resulting from Increased Membrane Permeability

Moe Nishimura ^{1,†}, Hiroyuki Fuchino ², Kaoru Takayanagi ¹, Hitomi Kawakami ², Hiroko Nakayama ^{3,4}, Nobuo Kawahara ^{2,5} and Yasuhito Shimada ^{1,3,6,*}

¹ Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; 318070@m.mie-u.ac.jp (M.N.); 316066@m.mie-u.ac.jp (K.T.)

² Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition, Hachimandai, Tsukuba, Ibaraki 305-0843, Japan; fuchino@nibiohn.go.jp (H.F.); h-kawakami@nibiohn.go.jp (H.K.); kawahara@nibiohn.go.jp (N.K.)

³ Zebrafish Drug Screening Center, Mie University, Tsu 514-8507, Japan; nakayama@innov.mie-u.ac.jp

⁴ Graduate School of Regional Innovation Studies, Mie University, Tsu, Mie 514-8507, Japan

⁵ The Kochi Prefectural Makino Botanical Garden, Godaisan, Kochi 781-8125, Japan

⁶ Department of Bioinformatics, Mie University Advanced Science Research Promotion Center, Tsu, Mie 514-8507, Japan

* Correspondence: shimada.yasuhito@mie-u.ac.jp; Tel.: +81-59-231-5411

† These authors contributed equally to this work.



Citation: Nishimura, M.; Fuchino, H.; Takayanagi, K.; Kawakami, H.; Nakayama, H.; Kawahara, N.; Shimada, Y. Toxicity of Jegosaponins A and B from *Styrax japonica* Siebold et al. Zuccarini in Prostate Cancer Cells and Zebrafish Embryos Resulting from Increased Membrane Permeability. *Int. J. Mol. Sci.* **2021**, *22*, 6354. <https://doi.org/10.3390/ijms22126354>

Academic Editor: Luca Del Giacco

Received: 11 May 2021

Accepted: 9 June 2021

Published: 14 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract: (1) Background: Screening of medicinal herbs is one of the most powerful approaches to identifying novel therapeutic molecules against many human diseases. To avoid potential harmful effects during medicinal use, toxicity testing is necessary in the early stages of drug discovery. The objective of this study was to identify the cytotoxic mechanisms of jegosaponin A and B from *Styrax japonica* Siebold et al. Zuccarini; (2) Methods: We screened Japanese medicinal herb extracts using PC-3 prostate cancer cells and found that a methanol extract isolated from the unripe fruit of *Styrax japonica* Siebold et al. Zuccarini (SJSZ) had an inhibitory effect on cell viability. We further performed fractionation assays with PC-3 cells and identified the bioactive compounds using LC/MS and NMR analysis. We clarified the toxic mechanisms of these compounds using PC-3 cells and zebrafish embryos; (3) Results: We identified two active molecules, jegosaponin A and jegosaponin B, in the inhibitory fractions of the methanol extract. These jegosaponins are toxic to zebrafish embryos during the early developmental stage. Jegosaponin A and B showed strong haemolytic activity in sheep defibrinated blood ($EC_{50} = 2.1 \mu\text{M}$, and $20.2 \mu\text{M}$, respectively) and increased the cell membrane permeability in PC-3 cells and zebrafish embryos, which were identified using a membrane non-permeable DRAQ7, a fluorescent nucleus staining dye; (4) We identified the cytotoxic compounds jegosaponin A and B from SJSZ, which we showed to exhibit cell membrane disruptive properties using cell- and zebrafish-based testing.

Keywords: screening; anti-cancer; toxicology



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Constituents of natural products are an important source of medicine [1], and as their chemical diversity can provide the core scaffolds for future medicines, a number of promising drug candidates, currently in development or in the market, originate from natural products [2]. Drug discovery from plants has been ongoing since ancient times and is still undergoing various modified protocols, such as high-throughput screening and in vivo testing, including in zebrafish [3–5]. In addition, there is an increasing use of herbs as traditional and alternative medicines, and there is a strong demand for more scientific evidence to evaluate their efficacy and safety.

Styrax japonica Siebold et al. Zuccarini (SJSZ) is a shrub of the family Syracaceae, native to Japan, China, and Korea. The species also possesses high commercial, nutritional, and therapeutic values, and has long been used conventionally by many communities for treating oral and dental diseases and respiratory ailments [6]. Several bioactive molecules have been identified in SJSZ in previous studies. For example, norlignan and styraxlignolide have anti-complement activity [7] and styraxoside A has anti-inflammatory effects in cultured cells [8]. In addition, phytylglycoprotein (38 kDa) from SJSZ suppresses cell proliferation in human carcinomatous cells [9,10] and mice [11].

As major physiological processes and gene expression pathways are highly conserved in vertebrates, zebrafish (*Danio rerio*) have been an attractive model for toxicological testing denoted by the zebrafish embryo acute toxicity test (ZFET) and can serve as an alternative model to rodents [12,13]. The Organisation for Economic Co-operation and Development (OECD) recommends the use of the ZFET for in vivo assessment of the safety of chemicals [14]. In addition, zebrafish embryos, larvae, and juveniles have transparent body walls, which enables live imaging using tissue-specific proteins and fluorescent dyes. For example, we previously evaluated the neurological toxicity of fluorescent indoline derivatives in zebrafish embryos [15,16].

The objective of this study was to identify the cytotoxic mechanisms of jegosaponin A and B from *Styrax japonica* Siebold et al. Zuccarini. As a preliminary study, we performed cell-based screening of 756 Japanese herb extracts using human prostate cancer cells and thereby identified the cytotoxicity of the extracts from unripe fruit of SJSZ. In this study, we identified two bioactive constituents, jegosaponin A and jegosaponin B, as underlying this cytotoxicity, and clarified the mechanism of cytotoxicity in cultured cells and zebrafish embryos.

2. Results

2.1. Jegosaponins from *Styrax japonica* Siebold et al. Zuccarini (SJSZ) Suppresses Cell Viability in PC-3 Prostate Cancer Cells

Cell-based screening identified that methanol extracts of SJSZ (10 µg/mL) strongly suppressed PC-3 cell viability. To determine the responsible constituents, we performed serial extraction (*n*-hexane, ethyl acetate, and *n*-butanol) and subsequent cell viability assays, and determined that the *n*-butanol extract strongly suppressed PC-3 cell viability (10 µg/mL each; Figure 1a). We further performed fractionation of the *n*-butanol extract, and again performed subsequent cell viability assays with the products, and identified that fractions 1, 5, and 6 suppressed PC-3 cell viability (Figure 1b). By LC/MS and NMR analyses, we found these fractions to contain jegosaponin A and jegosaponin B (Figure 1c), which suppressed PC-3 cell viabilities at lethal concentration 50 (LC₅₀) = 0.7 ± 0.0 µM and 1.6 ± 0.3 µM, respectively (Figure 1d). In addition, we confirmed that these jegosaponins also suppressed the viability of other human prostate cancer cell lines, namely DU145 and LNCaP (Figure S1).

2.2. Acute Toxicity of Jegosaponins in Zebrafish Embryos

To evaluate the in vivo toxicity of the jegosaponins, we performed a zebrafish embryo acute toxicity test (ZFET) according to the OECD guidelines [14]. After 120 h administration of jegosaponins from 5 h-post fertilization (hpf) embryos, LC₅₀ of jegosaponin A and B was 0.5 ± 0.1 µM and 1.3 ± 0.2 µM, respectively (Figure 2a). In the time-course experiments, we found that the toxicity of the jegosaponins 24 h after administration was almost the same as that at 120 h (Figure 2b; LC₅₀ of jegosaponin A and B was 0.7 ± 0.1 µM, and 1.4 ± 0.2 µM, respectively). This suggests that the toxicities of jegosaponins were exerted in a relatively short time. The typical phenotypes induced by jegosaponin A and B are represented in Figure 2c.




Figure 1. Jegosaponin A and B from unripe fruits of *Styrax japonica* Siebold et al. Zuccarini (SJSZ) suppress prostate cancer PC-3 cells. **(a)** BuOH extract of SJSZ suppresses PC-3 cell viability. $n = 8$, error bars indicate SD. **** $p < 0.0001$ compared to control (0.1% DMSO). **(b)** Fraction 1, 5 and 6 of BuOH extract of SJSZ suppresses cell viability in a dose-dependent manner. $n = 8$, error bars indicate SD. **** $p < 0.0001$ compared to control (0.1% DMSO). **(c)** Chemical structures of jegosaponin A and B. **(d)** Jegosaponin A and B suppress PC-3 cell viability after 48 h treatment. $n = 8$, error bars indicate SD. **** $p < 0.0001$ compared to control (0 μM jegosaponin A). ##### $p < 0.0001$ vs. control (0 μM jegosaponin B).




Figure 2. Zebrafish embryo acute toxicity test of jegosaponin A and B. **(a)** Blastula (5 hpf) embryos were exposed to jegosaponin A and B for 120 hpf. $n = 3$, * $p < 0.05$ and ** $p < 0.01$ vs. control (0 μM jegosaponin A); ### $p < 0.01$ vs. control (0 μM jegosaponin B) **(b)** Survival analysis on 24 hpf with jegosaponins exposure. * $p < 0.05$ and ** $p < 0.01$ vs. control (0 μM jegosaponin A); ### $p < 0.01$ vs. control (0 μM jegosaponin B). **(c)** Representative images of **(a)**.

2.3. Cytotoxic Mechanisms of Jegosaponin A and B

As saponins are well-known non-ionic surfactants, which can induce permeabilization of the cell membrane, we measured the haemolytic activities of jegosaponin A and B in sheep red blood cells. As shown in Figure 3a, the concentrations of the 50% haemolytic dosage (HD₅₀) in jegosaponin A and B were $2.1 \pm 0.4 \mu\text{M}$, and $20.2 \pm 2.4 \mu\text{M}$, respectively.




Figure 3. Jegosaponin A and B increase cell membrane permeability. (a) Haemolysis of RBCs by jegosaponin A and B. $n = 3$, error bars indicate SD. (b) Increase in cell membrane permeability of PC-3 cells treated with jegosaponin A and B. Purple indicates membrane impermeable DRAQ7-stained nucleus. (c) Quantitative analysis of (b). $n = 3$, error bars indicate SD. * $p < 0.05$ and ** $p < 0.01$ vs. control (0 μM jegosaponin A); # $p < 0.05$ and ## $p < 0.01$ vs. control (0 μM jegosaponin B). (d) Increase of cell membrane permeability of 48 hpf zebrafish by jegosaponin A and B. Purple indicates membrane impermeable DRAQ7-stained nucleus.

To evaluate the jegosaponin-induced increase in cell membrane permeability in PC-3 cells, we administered DRAQ7, a cell-impermeable DNA staining far-red fluorescent dye, with jegosaponin A and B (Figure 3b; purple indicates DRAQ7-stained nucleus). The nucleus DNA was stained in a time-dependent manner after treatment with either jegosaponin (EC₅₀ of jegosaponin A, $3.4 \pm 0.6 \mu\text{M}$; jegosaponin B, $6.0 \pm 1.2 \mu\text{M}$; Figure 3c), indicating that these jegosaponins disrupt the cell membrane to induce cytotoxicity. The negative control (0.1% DMSO) did not allow DRAQ7 to stain the nucleus.

Next, we performed DRAQ7 treatment on zebrafish larvae to validate whether jegosaponins could increase cell permeability under in vivo conditions. As shown in Figure 3d, after 30 min of exposure, jegosaponin A and B apparently increased DRAQ7 signals (purple) mainly in the tail regions, indicating that the jegosaponins increased cell membrane permeability in zebrafish (48 hpf) skin, allowing DRAQ7 incorporation into the nuclear DNA. In addition, the high concentrations of jegosaponin A and B (6 μM , and 12 μM , respectively) killed all embryos for 60 min.

3. Discussion

Saponins are glycosides and triterpene glycosides in plants and are considered useful in the treatment of human diseases, including cancer. Yoshikawa et al. previously identified jegosaponin A, B, C, and D from fresh fruits of SJSZ and determined their structures [17], but their biological activities have not yet been characterised. In this study, we found that SJSZ extract contains anti-cancer constituents, which act against human prostate cancer cells, as subsequently identified them as two jegosaponins, jegosaponin A and B. We further found that the cytotoxic effects of jegosaponin A and B were fast acting in both cultured cells and zebrafish embryos, implying that the main underlying mechanisms involve direct

toxicity, probably by inducing the destruction of the cell membrane, rather than by ROS accumulation or alteration of gene expression profiles in other bioactive constituents in SJSZ, such as 38 kDa glycoprotein [9,11]. Therefore, their use as anticancer drugs is difficult. As some saponins are reported to have apoptotic properties in cultured cells [18], we measured the activities of caspase-3 and caspase-7, direct executors of apoptosis, after treatment with jegosaponin A and B, and found no apparent induction of their activities even at sub-IC₅₀ concentrations (Figure S1).

In this study, we determined the HD₅₀ and LC₅₀ of jegosaponin A and B for the first time (Table 1). Although the chemical structures of jegosaponin A and B were quite similar (Figure 1d), all parameters determined in this study were higher in jegosaponin A than in jegosaponin B. Jegosaponin A and B are positional isomers of acetyl and hydroxyl groups, respectively. For the structure-activity relationship, as with other saponins, the triterpene moiety of both jegosaponin A and B is hydrophobic and the sugar moiety is hydrophilic, thus, they are considered to have sufficient surfactant activity. Jegosaponin B differs from jegosaponin A in that the acetyl group attached to the C-28 position (Figure 1c) has an axial configuration, so it is sterically repulsive to the tigloyl group attached to the C-21 position. In other words, the conformation of the bulky tigloyl group is expected to be very different between A and B, which is thought to be the reason for the difference in activity observed in this study. In fact, in jegosaponin B, the acetyl group and the tigloyl group are arranged in a 1,3-diaxial configuration, which is prone to steric repulsion, so it is likely that the tigloyl will face outward to mitigate repulsion, and the difference may be large.

Table 1. Toxicity summary of jegosaponin A and B.

| | RBC | PC-3 Cells | | Zebrafish | |
|---------------|----------------------------|------------------|------------------------|------------------|------------------|
| | Hemolysis HD ₅₀ | LC ₅₀ | DRAQ7 IC ₅₀ | LC ₅₀ | LC ₅₀ |
| | (1 h) | (48 h) | (1 h) | (120 h) | (24 h) |
| Jegosaponin A | 2.1 µM | 0.7 µM | 3.4 µM | 0.5 µM | 0.7 µM |
| Jegosaponin B | 20.2 µM | 1.6 µM | 6.0 µM | 1.3 µM | 1.4 µM |

In addition, jegosaponin A and B have an αβ-unsaturated carbonyl (Michael acceptor); therefore, if a strong nucleophilic reagent, such as the SH group is present in our assay system, Michael addition may occur irreversibly. For example, the SH group of the enzyme may attach to the Michael acceptor causing non-selective enzyme inhibition. To be honest, it is difficult to prove that this phenomenon did not occur in our assays. However, there are many natural products that have such substructures, such as sesquiterpenes and diterpenes from the Asteraceae family, but given that we were unable to identify any in our screening study, we believe that the effect is negligible in this assay.

Voutquenne et al. summarised the haemolytic activities of saponins based on their structures [19]. Compared to other saponins and sapogenins, the HD₅₀ of jegosaponin A and B are quite low, especially that jegosaponin A (HD₅₀ = 2.1 µM), which indicates the high toxicity of these molecules in mammals. The surfactant properties of saponins are generally used in a wide range of applications, including expectorants, detergents, and emulsification of fragrances and spices. In the tropics, they are also used to remove snails that serve as intermediate hosts to reduce schistosomiasis. Jegosaponin A and B have the strongest surfactant activity among the saponins and are expected to be used for these applications.

The ability of these jegosaponins to disrupt cell membranes was demonstrated in prostate cancer cells and zebrafish embryos (Figure 3). In zebrafish embryos, we found that the tail fin is quite sensitive to jegosaponin-induced membrane destruction, which allowed the incorporation of membrane impermeable DRAQ7 into the cells. For the first time, we visualised cell membrane permeabilisation *in vivo*, which could offer a tool for evaluating the toxicity of other detergents.

4. Materials and Methods

4.1. Instruments

LC/MS was performed using an Orbitrap Elite spectrometer (Thermo Fischer Scientific, Waltham, MA, USA) equipped with an electrospray ionisation (ESI) ion source. HPLC was conducted for purification on a Shimadzu LC-10ADvp series (Shimadzu, Tokyo, Japan). ^1H and ^{13}C -NMR spectra were acquired using a Bruker ASCEND 600 spectrometer (600 MHz; Sadis, Wissembourg, France).

4.2. Sample Materials

Unripe fruit from *Styrax japonica* Siebold et al. Zuccarini was collected from Ibaraki, Japan on 29 July 2013.

4.3. Isolation Procedure

After drying, the sample materials (5 g) were pulverised and extracted with methanol (50 mL) under two cycles of refluxing. The extract was then filtered, and the filtrate was evaporated to yield a syrup (1.16 g). A portion of the extract (500 mg) was suspended in water (50 mL) and then partitioned with *n*-hexane to remove the lipids. The aqueous layer was then further partitioned with ethyl acetate to extract low-polarity compounds, and the resulting aqueous layer was partitioned with *n*-butanol to extract glycoside compounds such as saponins. Finally, the remaining aqueous layer contained polar compounds, such as sugars and tannins. Subsequently, the *n*-butanol layer was evaporated, and the residue was subjected to column chromatography on silica gel (methanol-chloroform). The fractions (eluted with 20–50% methanol/chloroform) were combined and re-chromatographed using HPLC (column: Imtakt UK C-18, 20 mm \times 250 mm, solvent: 80% methanol/water, flow rate: 8 mL/min; Portland, OR, USA) to obtain compounds **1** (27 mg) and **2** (6 mg).

The chemical structures of **1** and **2** were determined by spectroscopic techniques, including 2D-NMR (COSY, HMQC, and HMBC) and LC/MS. Using high-resolution MS, **1** and **2** were formulated as $\text{C}_{61}\text{H}_{96}\text{O}_{27}$. The ^{13}C -NMR spectra of compounds **1** and **2** were similar. Four moles of hexose signals and triterpene moiety signals were observed; moreover, the existence of tigloyl and acetyl groups was deduced. Therefore, compounds **1** and **2** were supposed to be analogs of jegosaponin. However, there were large differences in signals around C-21, 22, and 28 between **1** and **2**; **1** and **2** were deduced to be isomers of tigloyl and acetyl groups. The positions of the tigloyl and acetyl groups were determined using the HMBC spectrum. Finally, **1** and **2** were identified as jegosaponin A and B by comparison with the literature data [17]. Details of these compounds are described in Supplementary Materials.

4.4. Cell Viability Assay

Human prostate cancer PC-3, DU146, and LNCaP cells were obtained from Riken Bioresource Center (Tokyo, Japan) and cultured in Dulbecco's modified Eagle medium-low glucose (DMEM; Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS; Biowest SAS, Nuaille, France) and 1% penicillin-streptomycin (Fujifilm Wako Pure Chemicals) at 37 °C in a humidified 5% CO_2 atmosphere. For screening, the cells were seeded (3×10^3 cells/well) in a 96-well plate and cultured for 24 h in DMEM supplemented with 1% FBS. The tested compounds were then administered to the cells. Forty-eight hours after administration, cell viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega, Madison WI, USA) according to the manufacturer's protocol. Luminescence signals were measured using a Victor2 microplate reader (PerkinElmer, Boston, MA, USA). For the negative control (0 μM jegosaponin A and B), 0.1% dimethyl sulfoxide (vehicle) was used. Cell viability was calculated as the ratio of the negative controls. The assay was performed in triplicate.

4.5. Zebrafish

Zebrafish AB strain (Zebrafish International Resource Center, Eugene, OR, USA) was maintained in our facility according to standard operational guidelines. All animal procedures were performed by the Ethics Committee of Mie University, according to the Japanese Animal Welfare Regulation 'Act on Welfare and Management of Animals' (Ministry of Environment of Japan), and complied with international guidelines.

4.6. Zebrafish Embryo Acute Toxicity Test (ZFET)

ZFETs were performed as previously reported [13]. In brief, blastula stage embryos (approximately 5 h post fertilisation (hpf)) were transferred into 6-well plates and exposed to jegosaponin A or B at 28 °C until 120 hpf. Each group contained nine fish in three triplicates. The number of surviving embryos was counted every 24 h.

4.7. Caspase 3/7 Assay

PC-3 cells were seeded (3×10^3 cells/well) in a 96-well plate in DMEM containing 10% FBS for 24 h and treated with the test compounds. Caspase-Glo 3/7 assay (Promega) was performed according to the manufacturer's instructions. Luminescence signals were measured using a Victor2 microplate reader (PerkinElmer).

4.8. Haemolysis Assay

A haemolysis assay was performed as previously reported [18]. Five millilitres of sheep defibrinated blood (Nippon Bio-Supp. Centre, Tokyo, Japan) was diluted in 45 mL of Dulbecco's phosphate-buffered saline (DPBS) to obtain a total volume of 50 mL. The cell suspension was centrifuged at $500 \times g$ for 5 min, and the supernatant was discarded. This procedure was repeated three times, and DPBS was added to the precipitate, and the red blood cell (RBC) count was adjusted to $\sim 5 \times 10^8$ cells/mL. The RBC suspension (500 μ L) was placed into a 1.5 mL storage tube, and the reagent was administered and incubated for 30 min on ice. Complete (100%) haemolysis was achieved with 1% Triton X-100 in RBC suspension. The cell suspension was then centrifuged at $500 \times g$ for 5 min. The haemoglobin concentration in the supernatant was measured by measuring the UV absorbance at 540 nm.

4.9. DRAQ7 Membrane Permeability Assay

PC-3 cells were seeded (4×10^3 cells/well) in ibidi 8-well μ -Slide (Ibidi, Munich, Germany) in DMEM supplemented with 10% FBS and cultured for 24 h. Then, DRAQ7 (DRAQ7 DROP & GO; Biostatus, Shephed, UK) and the tested compounds were added to the cells. After an appropriate time, the cells were imaged using a BZ-X710 fluorescence microscope (Keyence, Tokyo, Japan). For zebrafish embryos, 48 hpf embryos were treated with DRAQ7 and the tested compounds and imaged using a BZ-X710 fluorescent microscope.

4.10. Statistics

The data were statistically analysed using Student's t-test or one-way analysis of variance with the Bonferroni-Dunn multiple comparison procedure, depending on the number of comparisons to be performed, using GraphPad Prism version 8 (GraphPad Software, San Diego, CA, USA). A p-value of less than 0.05, denoted the presence of a statistically significant difference between treatments.

5. Conclusions

We extracted cytotoxic jegosaponin A and jegosaponin B from unripe fruits of SJSZ, and characterised their strong detergent activities *in vitro* and *in vivo*. In addition to the traditional haemolysis assay, we also demonstrated their ability to disrupt cell membranes using a cell-impermeable fluorescent dye with cultured cells and zebrafish embryos. We consider that our new technologies are likely to assist other researchers in evaluating or analysing the cytotoxic mechanisms of other compounds.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/ijms22126354/s1>, Supplementary Methods: Details of the two compounds. Figure S1: Jegosaponin A and B suppress viability of human prostate cancer cells, Figure S2: Jegosaponin A and B do not affect caspase 3/7 activities in PC-3 cells. Jegosaponin A-1H-NMR, Jegosaponin A-13C-NMR, Jegosaponin B-1H-NMR, Jegosaponin B-13C-NMR.

Author Contributions: Conceptualisation, N.K. and Y.S.; methodology, M.N., H.F., K.T., and H.N.; validation, Y.S.; formal analysis, M.N.; investigation, Y.S.; resources, H.F. and H.K.; data curation, Y.S.; writing—original draft preparation, M.N.; writing—review and editing, Y.S.; supervision, Y.S.; funding acquisition, Y.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: All animal procedures were performed according to Japan's Act on Welfare and Management of Animals (Ministry of Environment of Japan) and complied with international guidelines. Ethical approval from the local Institutional Animal Care and Use Committee was not sought, as this law does not mandate the protection of fish.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank Rie Ikeyama, Takako Taguchi, and Azusa Kato for their secretarial assistance, and Masako Inoue for breeding zebrafish.

Conflicts of Interest: The authors declare no conflict of interest directly relevant to the content of this manuscript.

References

1. Chin, Y.W.; Balunas, M.J.; Chai, H.B.; Kinghorn, A.D. Drug discovery from natural sources. *AAPS J.* **2006**, *8*, E239–E253. [[CrossRef](#)] [[PubMed](#)]
2. Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. *Biochim. Biophys. Acta* **2013**, *1830*, 3670–3695. [[CrossRef](#)] [[PubMed](#)]
3. Chensom, S.; Shimada, Y.; Nakayama, H.; Yoshida, K.; Kondo, T.; Katsuzaki, H.; Hasegawa, S.; Mishima, T. Determination of Anthocyanins and Antioxidants in 'Titanibicus' Edible Flowers In Vitro and In Vivo. *Plant Foods Hum. Nutr.* **2020**, *75*, 265–271. [[CrossRef](#)] [[PubMed](#)]
4. Zhang, S.; An, L.; Li, Z.; Wang, X.; Wang, H.; Shi, L.; Bao, J.; Lan, X.; Zhang, E.; Lall, N.; et al. Structural elucidation of an immunological arabinan from the rhizomes of *Ligusticum chuanxiong*, a traditional Chinese medicine. *Int. J. Biol. Macromol.* **2021**, *170*, 42–52. [[CrossRef](#)] [[PubMed](#)]
5. Balkrishna, A.; Solleti, S.K.; Verma, S.; Varshney, A. Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. *Molecules* **2020**, *25*, 5091. [[CrossRef](#)] [[PubMed](#)]
6. Park, K.R.; Kim, S.; Cho, M.; Kang, S.W.; Yun, H.M. Effects of PIN on Osteoblast Differentiation and Matrix Mineralization through Runt-Related Transcription Factor. *Int. J. Mol. Sci.* **2020**, *21*, 9579. [[CrossRef](#)] [[PubMed](#)]
7. Min, B.S.; Oh, S.R.; Ahn, K.S.; Kim, J.H.; Lee, J.; Kim, D.Y.; Kim, E.H.; Lee, H.K. Anti-complement activity of norlignans and terpenes from the stem bark of *Styrax japonica*. *Planta Med.* **2004**, *70*, 1210–1215. [[CrossRef](#)] [[PubMed](#)]
8. Yun, K.J.; Min, B.S.; Kim, J.Y.; Lee, K.T. Styraxoside A isolated from the stem bark of *Styrax japonica* inhibits lipopolysaccharide-induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in RAW 264.7 cells by suppressing nuclear factor-kappa B activation. *Biol. Pharm. Bull.* **2007**, *30*, 139–144. [[CrossRef](#)] [[PubMed](#)]
9. Lee, J.; Lim, K.T. Phytoglycoprotein (38 kDa) induces cell cycle (G₀/G₁) arrest and apoptosis in HepG2 cells. *J. Cell Biochem.* **2011**, *112*, 3129–3139. [[CrossRef](#)] [[PubMed](#)]
10. Lee, J.; Lim, K.T. Modulatory effect of phytoglycoprotein (38 kDa) on cyclin D1/CDK4 in BNL CL.2 cells induced by N-methyl-N'-nitro-N-nitrosoguanidine. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2012**, *385*, 181–190. [[CrossRef](#)] [[PubMed](#)]
11. Lee, J.; Lim, K.T. SJSZ glycoprotein (38 kDa) inhibits cell cycle and oxidative stress in N-methyl-N'-nitro-N-nitrosoguanidine-induced ICR mice. *Anticancer Agents Med. Chem.* **2013**, *13*, 647–653. [[CrossRef](#)] [[PubMed](#)]
12. Hill, A.J.; Teraoka, H.; Heideman, W.; Peterson, R.E. Zebrafish as a model vertebrate for investigating chemical toxicity. *Toxicol. Sci.* **2005**, *86*, 6–19. [[CrossRef](#)] [[PubMed](#)]
13. Kawada, T.; Kuroyanagi, J.; Okazaki, F.; Taniguchi, M.; Nakayama, H.; Suda, N.; Abiko, S.; Kaneco, S.; Nishimura, N.; Shimada, Y. An Integrative Evaluation Method for the Biological Safety of Down and Feather Materials. *Int. J. Mol. Sci.* **2019**, *20*, 1434. [[CrossRef](#)] [[PubMed](#)]

14. Busquet, F.; Strecker, R.; Rawlings, J.M.; Belanger, S.E.; Braunbeck, T.; Carr, G.J.; Cenijn, P.; Fochtman, P.; Gourmelon, A.; Hübler, N.; et al. OECD validation study to assess intra- and inter-laboratory reproducibility of the zebrafish embryo toxicity test for acute aquatic toxicity testing. *Regul. Toxicol. Pharmacol.* **2014**, *69*, 496–511. [[CrossRef](#)] [[PubMed](#)]
15. Nishimura, Y.; Yata, K.; Nomoto, T.; Ogiwara, T.; Watanabe, K.; Shintou, T.; Tsuboyama, A.; Okano, M.; Umemoto, N.; Zhang, Z.; et al. Identification of a novel indoline derivative for in vivo fluorescent imaging of blood-brain barrier disruption in animal models. *ACS Chem. Neurosci.* **2013**, *4*, 1183–1193. [[CrossRef](#)] [[PubMed](#)]
16. Watanabe, K.; Nishimura, Y.; Nomoto, T.; Umemoto, N.; Zhang, Z.; Zhang, B.; Kuroyanagi, J.; Shimada, Y.; Shintou, T.; Okano, M.; et al. In vivo assessment of the permeability of the blood-brain barrier and blood-retinal barrier to fluorescent indoline derivatives in zebrafish. *BMC Neurosci.* **2012**, *13*, 101. [[CrossRef](#)] [[PubMed](#)]
17. Yoshikawa, K.; Hirai, H.; Tanaka, M.; Arihara, S. Antisweet natural products. XV. Structures of Jegosaponins A-D from *Styrax japonica* Sieb. et Zucc. *Chem. Pharm. Bull.* **2000**, *48*, 1093–1096. [[CrossRef](#)] [[PubMed](#)]
18. Waheed, A.; Barker, J.; Barton, S.J.; Owen, C.P.; Ahmed, S.; Carew, M.A. A novel steroidal saponin glycoside from *Fagonia indica* induces cell-selective apoptosis or necrosis in cancer cells. *Eur. J. Pharm. Sci.* **2012**, *47*, 464–473. [[CrossRef](#)] [[PubMed](#)]
19. Voutquenne, L.; Lavaud, C.; Massiot, G.; Le Men-Olivier, L. Structure-activity relationships of haemolytic saponins. *Pharm. Biol.* **2002**, *40*, 253–262. [[CrossRef](#)]